Mereo BioPharma Group plc (Mereo) (MREO): Price and Financial Metrics


Mereo BioPharma Group plc (Mereo) (MREO): $0.53

0.04 (+8.76%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MREO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MREO Stock Price Chart Interactive Chart >

Price chart for MREO

MREO Price/Volume Stats

Current price $0.53 52-week high $3.75
Prev. close $0.49 52-week low $0.30
Day low $0.49 Volume 900,000
Day high $0.57 Avg. volume 819,556
50-day MA $0.87 Dividend yield N/A
200-day MA $1.66 Market Cap 62.34M

Mereo BioPharma Group plc (Mereo) (MREO) Company Bio


Mereo BioPharma Group plc (Mereo) operates as a clinical stage biopharmaceutical company. The Company develops medicines for rare and specialty diseases. Mereo serves the healthcare sector globally.


MREO Latest News Stream


Event/Time News Detail
Loading, please wait...

MREO Latest Social Stream


Loading social stream, please wait...

View Full MREO Social Stream

Latest MREO News From Around the Web

Below are the latest news stories about Mereo Biopharma Group plc that investors may wish to consider to help them evaluate MREO as an investment opportunity.

Do Hedge Funds Love Mereo BioPharma Group plc (MREO)?

In this article you are going to find out whether hedge funds think Mereo BioPharma Group plc (NASDAQ:MREO) is a good investment right now.

Insider Monkey | January 12, 2022

UAB and Mereo BioPharma Group post positive results from Covid-19 clinical trial

A UAB investigated covid treatment from Mereo BioPharma Group shows positive results in early clinical trial.

Yahoo | December 29, 2021

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Mereo Biopharma Group Plc (MREO)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and Mereo Biopharma Group Plc (MREO – Research Report) with bullish sentiments. Merck & Company (MRK) In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company, with a price target of $100.00. The company's shares closed last Wednesday at $76.05. According to TipRanks.

Howard Kim on TipRanks | December 22, 2021

Investors Take Advantage Of -3.03% Loss In Mereo BioPharma Group plc (NASDAQ: MREO)

Mereo BioPharma Group plc (NASDAQ:MREO) traded at $1.60 at last check on Wednesday, December 22, made a downward move of -3.03% on its previous days price. Looking at the stock we see that its previous close was $1.65 and the beta (5Y monthly) reads 1.49 with the days price range being $1.62 $1.70. In Investors Take Advantage Of -3.03% Loss In Mereo BioPharma Group plc (NASDAQ: MREO) Read More »

Stocks Register | December 22, 2021

UAB and Mereo Announce Positive Top-line Results from “COSTA” a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease

Alvelestat reported safe and well-tolerated in patients with COVID-19 Alvelestat, on top of standard of care resulted in a more rapid time to improvement in WHO Disease Severity score of >=2 in the first 5-7 days compared to placebo plus standard of care LONDON and REDWOOD CITY, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- The University of Alabama at Birmingham (UAB) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced top-line data from a Phase 1b/2 clinical trial evaluating alvelestat,

Yahoo | December 22, 2021

Read More 'MREO' Stories Here

MREO Price Returns

1-mo -28.38%
3-mo N/A
6-mo -72.40%
1-year -83.44%
3-year -88.20%
5-year N/A
YTD -66.88%
2021 -55.31%
2020 9.15%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7503 seconds.